Publication number: 20140275488
Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
Type:
Application
Filed:
March 11, 2014
Publication date:
September 18, 2014
Applicant:
PHARMABCINE INC.
Inventors:
Jin-San YOO, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
Patent number: 8779106
Abstract: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.
Type:
Grant
Filed:
July 30, 2012
Date of Patent:
July 15, 2014
Assignee:
Incyte Corporation
Inventors:
Vicki S. Elliott, Reena Khare, Thomas W. Richardson, Joseph P. Marquis, Anita Swarnakar, April J. A. Hafalia, Shanya D. Becha, Narinder K. Chawla-Walia, Mariah R. Baughn, Soo Yeun Lee, Uyen K. Tran, Henry Yue, Danniel B. Nguyen, Michael B. Thornton, Rajagopal Gururajan, Ameena R. Gandhi, Yan Lu, Monique G. Yao, Joana X. Li, Wen Luo, Ernestine A. Lee, Ian J. Forsythe, Craig H. Ison, Amy D. Wilson, Pei Jin
Publication number: 20140193836
Abstract: The present invention provides a method for selecting dopaminergic neuron progenitor cells, which comprises detecting any one or more of markers selected from the group consisting of CD15 (SSEA-1), CD24, CD46, CD47, CD49b, CD57, CD58, CD59, CD81, CD90, CD98, CD147, CD184, Disalogangliosid GD2, SSEA-4, CD49f, SERINC4, CCR9, PHEX, TMPRSS11E, HTR1E, SLC25A2, Ctxn3, Cc17, Chrnb4, Chrna3, Kcnv2, Grm2, Syt2, Lim2, Mboat1, St3ga16, Slc39a12, Tacr1, Lrtm1, Dscam and CD201.
Type:
Application
Filed:
July 27, 2012
Publication date:
July 10, 2014
Applicants:
EISAI R&D MANAGEMENT CO., LTD., KYOTO UNIVERSITY
Inventors:
Jun Takahashi, Daisuke Doi, Bumpei Samata, Yuichi Ono